医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Everest Group Recognizes HCL as a Leader and Star Performer in the Life Sciences IT Outsourcing Market

2013年11月26日 PM11:55
このエントリーをはてなブックマークに追加


 

SUNNYVALE, Calif. & NOIDA, India

HCL Technologies, a leading global IT services company today announced that it has been recognized as a “Leader” and “Star Performer” category in life sciences IT outsourcing by leading advisory and research firm Everest Group in its report, “IT Outsourcing in Life Sciences Industry Service Provider Landscape with PEAK Matrix™ Assessment and Profile Compendium 2013.”

HCL was recognized for its continual growth on a large scale, and for its significant investment in life science proprietary solutions.

This report assesses 14 ITO service providers in the life sciences vertical with a focus on large (TCV>US$25 million), annuity based, and multi-year (>3 year) application outsourcing relationships. The service providers were mapped on the Everest Group’s performance, experience, ability, knowledge (PEAK) Matrix, a composite index of range of distinct metrics related to provider’s capability and market success across two key dimensions – market success measured by the number, scale and growth of large life sciences ITO contracts and delivery capabilities measured by scale of operations, scope, enabling domain investments, and delivery footprint.

“The Life Sciences industry is keenly adopting next-generation IT with an eye on enabling strategic initiatives,” said Jimit Arora, Vice President of Everest Group. “HCL’s investments in its services portfolio and domain solutions have created success in large, multi-year IT service contracts for life sciences customers. HCL not only continued to maintain its position as a Leader on the PEAK Matrix but also enhanced its capabilities and achieved above average growth to be a Star Performer.”

R Srikrishna, President – Infrastructure Services and Life Sciences & Healthcare, HCL said, “Everest recognition is a great acknowledgement of HCL’s strong momentum and success in its life sciences business, resulting from our strong focus on solution development and significant pharma deal wins in the application, infrastructure and ERP space globally. During the last financial year HCL’s healthcare and life sciences posted incremental revenue of 45.2%, which is way ahead when compared to the other leading operating players for the same time period.”

CONTACT

HCL America Inc.
Avena Suri, 949-310-7290
Avena.suri@hcl.com
or
Matter
Communications

Andrea Dunbeck, 978-518-4555
adunbeck@matternow.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent